PDCD1 and neoplasm: Employing immune checkpoint inhibitors (ICIs), like programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) antibodies, has drastically improved clinical outcomes for tumor patients [1, 2].